Anne-Marie Leuck1, James R Johnson2, Matthew A Hunt3, Kush Dhody4, Kazem Kazempour4, Patricia Ferrieri5, Susan Kline6. 1. Department of Medicine, University of Minnesota, Minneapolis, MN. Electronic address: leuck002@umn.edu. 2. Department of Medicine, University of Minnesota, Minneapolis, MN; Department of Medicine, Veterans Affairs Healthcare System, Minneapolis, MN. 3. Department of Neurosurgery, University of Minnesota, Minneapolis, MN. 4. Amarex Clinical Research, Germantown, MD. 5. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN; Department of Pediatrics, University of Minnesota, Minneapolis, MN. 6. Department of Medicine, University of Minnesota, Minneapolis, MN.
Abstract
BACKGROUND: The purpose of this study was to evaluate the safety of a novel silver-impregnated Foley catheter system designed to prevent catheter-associated bacteriuria and funguria, assess recruitment feasibility for a future pivotal trial, and preliminarily assess efficacy. METHODS: This single-center, randomized controlled trial at a university hospital involved adult neurosurgical patients expected to have a urinary catheter for ≥24 hours. Subjects were randomized to a novel silver-impregnated (test) Foley catheter system or a control system. They were followed for 30 days (or until discharge) while catheterized and for up to 48 hours after catheter removal, with daily bacteriuria testing and assessment for symptoms of infection and catheter intolerance. RESULTS:Ninety-five subjects were randomized (intention-to-treat [ITT] population). Of these, 61 subjects (64%) had a catheter for ≥24 hours without perioperative antibiotics beyond 24 hours (evaluable population). In the ITT population, 11 of 95 (12%) subjects had an asymptomatic bacteriuria (ABU) event. Compared with controls, test system recipients had a trend toward longer time to ABU in the ITT population (P = .08, log-rank test) and a longer time to ABU in the evaluable population (P = .03). All 6 ABU events caused by gram-negative bacilli occurred in the control group. CONCLUSION: In this pilot randomized trial the test system was well tolerated and seemingly effective in preventing catheter-associated bacteriuria, especially with gram-negative bacilli. A pivotal study is warranted.
RCT Entities:
BACKGROUND: The purpose of this study was to evaluate the safety of a novel silver-impregnated Foley catheter system designed to prevent catheter-associated bacteriuria and funguria, assess recruitment feasibility for a future pivotal trial, and preliminarily assess efficacy. METHODS: This single-center, randomized controlled trial at a university hospital involved adult neurosurgical patients expected to have a urinary catheter for ≥24 hours. Subjects were randomized to a novel silver-impregnated (test) Foley catheter system or a control system. They were followed for 30 days (or until discharge) while catheterized and for up to 48 hours after catheter removal, with daily bacteriuria testing and assessment for symptoms of infection and catheter intolerance. RESULTS: Ninety-five subjects were randomized (intention-to-treat [ITT] population). Of these, 61 subjects (64%) had a catheter for ≥24 hours without perioperative antibiotics beyond 24 hours (evaluable population). In the ITT population, 11 of 95 (12%) subjects had an asymptomatic bacteriuria (ABU) event. Compared with controls, test system recipients had a trend toward longer time to ABU in the ITT population (P = .08, log-rank test) and a longer time to ABU in the evaluable population (P = .03). All 6 ABU events caused by gram-negative bacilli occurred in the control group. CONCLUSION: In this pilot randomized trial the test system was well tolerated and seemingly effective in preventing catheter-associated bacteriuria, especially with gram-negative bacilli. A pivotal study is warranted.
Authors: Evelyn Lo; Lindsay Nicolle; David Classen; Kathleen M Arias; Kelly Podgorny; Deverick J Anderson; Helen Burstin; David P Calfee; Susan E Coffin; Erik R Dubberke; Victoria Fraser; Dale N Gerding; Frances A Griffin; Peter Gross; Keith S Kaye; Michael Klompas; Jonas Marschall; Leonard A Mermel; David A Pegues; Trish M Perl; Sanjay Saint; Cassandra D Salgado; Robert A Weinstein; Robert Wise; Deborah S Yokoe Journal: Infect Control Hosp Epidemiol Date: 2008-10 Impact factor: 3.254
Authors: J W Weinstein; D Mazon; E Pantelick; P Reagan-Cirincione; L M Dembry; W J Hierholzer Journal: Infect Control Hosp Epidemiol Date: 1999-08 Impact factor: 3.254
Authors: Sanjay Saint; Jennifer A Meddings; David Calfee; Christine P Kowalski; Sarah L Krein Journal: Ann Intern Med Date: 2009-06-16 Impact factor: 25.391
Authors: Stefan D Holubar; Traci Hedrick; Ruchir Gupta; John Kellum; Mark Hamilton; Tong J Gan; Monty G Mythen; Andrew D Shaw; Timothy E Miller Journal: Perioper Med (Lond) Date: 2017-03-03